HCmed to expand inhalation treatment business with new CDMO offering
The Taiwan-based nebuliser specialist has signed an MoU with Formosa Laboratories, and Formosa Pharmaceuticals to form a biopharma one-stop-shop
In response to growing demand for respiratory treatment drugs Taiwan's HCmed Innovations has signed a Memorandum of Understanding (MoU) with Formosa Laboratories and Formosa Pharmaceuticals to expand its inhalation treatment businss, providing contract development and manufacturing services.
The tripartite agreement plans to integrate HCmed's technology in developing customised vibrating mesh nebulisers with Formosa Laboratories' drug development and production experience of APIs, ADCs, and injections, and Formosa Pharmaceuticals' APNT (Activus Pure Nanoparticle Technology) nanotechnology platform, to become a one-stop-shop in the biopharmaceutical industry as a full-service CDMO.
During the last 2 years, the COVID-19 pandemic has pushed demand for respiratory treatment drugs; it also accounts for the uptick in demand for developing respiratory drugs, so much so that several well-known global pharmaceutical companies have incorporated HCmed's proprietary mesh technology into the development of their inhaled products.
By focusing on drug-device combination products, the three parties believe their CDMO offering can provide their pharma partners with a platform to deliver drugs, and integrated services that extend to drug development, mass production, and product packaging.
According to Jason Cheng, CEO of HCmed, by delivering such services, they expect to shorten combination product development time and reduce costs, thereby creating "win-win" relationships.
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.